## Acute Mania Management in Bipolar I Disorder ### First-Line Pharmacological Options **Key Point:** SSRIs are NOT first-line agents for acute mania in Bipolar I disorder; they may paradoxically worsen or precipitate manic episodes and are contraindicated as monotherapy. | Agent Class | Role in Acute Mania | Evidence | Notes | |---|---|---|---| | Lithium | First-line | Gold standard, rapid onset | Narrow therapeutic window (0.6–1.2 mEq/L); requires monitoring | | Valproate/Divalproex | First-line | Excellent efficacy | Faster onset than lithium; preferred in acute agitation | | Atypical antipsychotics | First-line | Robust RCT data | Quetiapine, olanzapine, aripiprazole all FDA-approved | | SSRIs | Contraindicated | Risk of mood destabilization | May trigger or worsen mania; only safe with mood stabilizer co-prescription | ### Why SSRIs Are Problematic in Bipolar I Mania 1. **Mood destabilization:** Monotherapy with SSRIs increases risk of manic/hypomanic switch. 2. **Lack of efficacy:** No evidence for benefit in acute mania; designed for depression. 3. **Clinical guideline consensus:** CANMAT, APA, and NICE guidelines explicitly recommend against SSRI monotherapy in Bipolar I disorder. **High-Yield:** If an SSRI is deemed necessary (e.g., for comorbid depression in a bipolar patient), it MUST be co-prescribed with a mood stabilizer (lithium or anticonvulsant) or antipsychotic to prevent manic switch. **Clinical Pearl:** In this case, the patient requires immediate mood stabilization with lithium, valproate, or an atypical antipsychotic—not an SSRI. ### Recommended Approach for This Patient - **Acute phase:** Atypical antipsychotic (e.g., olanzapine 10–20 mg/day or quetiapine 300–600 mg/day) ± lithium or valproate. - **Maintenance:** Lithium or valproate monotherapy or combination therapy to prevent relapse.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.